Proderm technology: a water- based lipid delivery system for dermatitis that penetrates viable epidermis and has antibacterial effects.
Adult
Anti-Bacterial Agents
/ administration & dosage
Dermatitis, Allergic Contact
/ drug therapy
Dermatitis, Atopic
/ drug therapy
Drug Delivery Systems
/ methods
Emollients
/ administration & dosage
Epidermis
/ drug effects
Escherichia coli
/ isolation & purification
Female
Healthy Volunteers
Humans
Lipids
/ chemistry
Male
Methicillin-Resistant Staphylococcus aureus
/ isolation & purification
Permeability
Retrospective Studies
Skin Cream
/ administration & dosage
Treatment Outcome
Water
/ chemistry
Young Adult
Antimicrobial
Dermatitis
Epidermis
Escherichia coli
Fatty acids
Penetration
Physiological lipids
Skin barrier
Staphylococcus aureus
Journal
BMC dermatology
ISSN: 1471-5945
Titre abrégé: BMC Dermatol
Pays: England
ID NLM: 100968541
Informations de publication
Date de publication:
22 01 2019
22 01 2019
Historique:
received:
03
03
2018
accepted:
14
01
2019
entrez:
24
1
2019
pubmed:
24
1
2019
medline:
15
2
2020
Statut:
epublish
Résumé
A defective skin barrier and bacterial colonization are two important factors in maintenance and progression of atopic dermatitis and chronic allergic/irritant hand dermatitis. A water-based lipid delivery system containing physiologic lipids was previously shown to be a useful adjunct in the treatment of hand dermatitis. We tested the ability of this formulation to penetrate into the viable epidermis and in addition assessed its antibacterial properties. Epidermal penetration of the product was assessed by fluorescence microscopy. Recovery of Escherichia coli and Staphylococcus aureus MRSA from skin treated with Neosalus® foam was quantified. Components of Neosalus® penetrated the stratum corneum and were distributed throughout the viable epidermis. Neosalus® significantly decreased recovery of both Staphylococcus aureus and Escherichia coli from the skin surface. The ability of components of Neosalus® to be taken up into the viable epidermis and potentially made available for incorporation into the barrier lipids, combined with antibacterial properties, indicate that this formulation may be valuable not only in chronic hand dermatitis, but also in various other forms of dermatitis. Current Controlled Trials ISRCTN18191379 , 28/12/2018, retrospectively registered.
Sections du résumé
BACKGROUND
A defective skin barrier and bacterial colonization are two important factors in maintenance and progression of atopic dermatitis and chronic allergic/irritant hand dermatitis. A water-based lipid delivery system containing physiologic lipids was previously shown to be a useful adjunct in the treatment of hand dermatitis. We tested the ability of this formulation to penetrate into the viable epidermis and in addition assessed its antibacterial properties.
METHODS
Epidermal penetration of the product was assessed by fluorescence microscopy. Recovery of Escherichia coli and Staphylococcus aureus MRSA from skin treated with Neosalus® foam was quantified.
RESULTS
Components of Neosalus® penetrated the stratum corneum and were distributed throughout the viable epidermis. Neosalus® significantly decreased recovery of both Staphylococcus aureus and Escherichia coli from the skin surface.
CONCLUSIONS
The ability of components of Neosalus® to be taken up into the viable epidermis and potentially made available for incorporation into the barrier lipids, combined with antibacterial properties, indicate that this formulation may be valuable not only in chronic hand dermatitis, but also in various other forms of dermatitis.
TRIAL REGISTRATION
Current Controlled Trials ISRCTN18191379 , 28/12/2018, retrospectively registered.
Identifiants
pubmed: 30670022
doi: 10.1186/s12895-019-0082-8
pii: 10.1186/s12895-019-0082-8
pmc: PMC6343233
doi:
Substances chimiques
Anti-Bacterial Agents
0
Emollients
0
Lipids
0
Water
059QF0KO0R
Banques de données
ISRCTN
['ISRCTN18191379']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Références
Skin Pharmacol Physiol. 2008;21(3):124-35
pubmed: 18523410
J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):387-96
pubmed: 1564142
Br J Dermatol. 1974 May;90(5):525-30
pubmed: 4601016
Am J Contact Dermat. 1999 Sep;10(3):119-26
pubmed: 10444104
J Am Acad Dermatol. 1999 May;40(5 Pt 1):783-5
pubmed: 10321615
Antimicrob Agents Chemother. 1972 Jul;2(1):23-8
pubmed: 4670656
Br J Dermatol. 2016 Oct;175(4):687-95
pubmed: 26994362
Exp Dermatol. 2008 Dec;17(12):1063-72
pubmed: 19043850
Int J Dermatol. 2014 Jan;53(1):27-33
pubmed: 23879225
Biol Res. 2015 Jan 23;48:9
pubmed: 25761515
Int J Dermatol. 2011 Jun;50(6):682-8
pubmed: 21595661
Arch Dermatol. 1995 Jul;131(7):809-16
pubmed: 7611797
Appl Microbiol Biotechnol. 2010 Feb;85(6):1629-42
pubmed: 19956944
Plast Reconstr Surg. 2010 Feb;125(2):719-24
pubmed: 20124857
Pediatrics. 2009 May;123(5):e808-14
pubmed: 19403473
Am J Contact Dermat. 2000 Sep;11(3):165-9
pubmed: 11012005
Lipids Health Dis. 2006 May 03;5:12
pubmed: 16672068
Derm Beruf Umwelt. 1990 Mar-Apr;38(2):50-3
pubmed: 2187664
J Drugs Dermatol. 2013 Jul 1;12(7):s85-91
pubmed: 23884506